All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).
1 finding from 1 review
Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality
1 finding from 1 review
Non‐fatal MI
1 finding from 1 review
Non‐fatal stroke
1 finding from 1 review
End‐stage renal disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes all‐cause mortality compared with thiazolidinediones (very low certainty).
1 finding from 1 review
SAEs
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found